[HTML][HTML] Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

F Ye, S Dewanjee, Y Li, NK Jha, ZS Chen, A Kumar… - Molecular cancer, 2023 - Springer
Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …

[HTML][HTML] Immunotherapy in breast cancer: an overview of current strategies and perspectives

V Debien, A De Caluwé, X Wang… - NPJ Breast …, 2023 - nature.com
Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and …

HM Nguyen, W Paulishak, M Oladejo, L Wood - Breast Cancer, 2023 - Springer
Heterogeneity of the tumor microenvironment (TME) and the lack of a definite targetable
receptor in triple-negative breast cancer (TNBC) has carved a niche for this cancer as a …

[HTML][HTML] A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer

C Puig-Saenz, JRD Pearson, JE Thomas, SEB McArdle - Biomedicines, 2023 - mdpi.com
Immunotherapy represents an attractive avenue for cancer therapy due to its tumour
specificity and relatively low frequency of adverse effects compared to other treatment …